Alithea Genomics

Executive Summary

Alithea Genomics, founded in 2019 and headquartered in Lausanne, Switzerland, is a biotechnology company specializing in large-scale, high-throughput RNA sequencing solutions. The company's proprietary technologies enable extraction-free, massively multiplexed library preparation from diverse sample types including cells, tissues, and blood. By streamlining the RNA sequencing workflow, Alithea aims to significantly reduce time and cost while maintaining high-quality data, addressing key bottlenecks in genomics research. The company targets academic institutions, pharmaceutical companies, and clinical research organizations that require scalable and efficient transcriptomic analysis. Despite being private with undisclosed funding and valuation, Alithea has positioned itself in the competitive NGS library preparation market, differentiated by its focus on extraction-free, high-multiplexing capabilities. As the demand for large-scale genomics data grows, particularly in drug development and precision medicine, Alithea's solutions could capture meaningful market share. However, the company faces competition from established players like Illumina and 10x Genomics, as well as emerging startups. With no disclosed revenue or clinical pipeline, the near-term outlook hinges on commercial traction and strategic partnerships.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of next-generation RNA sequencing kit targeting single-cell applications60% success
• TBDPartnership or collaboration with a major pharmaceutical or diagnostics company40% success
• Q4 2026Series A or B funding round to scale manufacturing and sales70% success